473 related articles for article (PubMed ID: 30867573)
1. Paraneoplastic neurological syndromes in the era of immune-checkpoint inhibitors.
Graus F; Dalmau J
Nat Rev Clin Oncol; 2019 Sep; 16(9):535-548. PubMed ID: 30867573
[TBL] [Abstract][Full Text] [Related]
2. Paraneoplastic Autoimmune Neurological Syndromes and the Role of Immune Checkpoint Inhibitors.
Duong SL; Prüss H
Neurotherapeutics; 2022 Apr; 19(3):848-863. PubMed ID: 35043373
[TBL] [Abstract][Full Text] [Related]
3. Increased frequency of anti-Ma2 encephalitis associated with immune checkpoint inhibitors.
Vogrig A; Fouret M; Joubert B; Picard G; Rogemond V; Pinto AL; Muñiz-Castrillo S; Roger M; Raimbourg J; Dayen C; Grignou L; Pallix-Guyot M; Lannoy J; Ducray F; Desestret V; Psimaras D; Honnorat J
Neurol Neuroimmunol Neuroinflamm; 2019 Nov; 6(6):. PubMed ID: 31454760
[TBL] [Abstract][Full Text] [Related]
4. A case series of PD-1 inhibitor-associated paraneoplastic neurologic syndromes.
Gill A; Perez MA; Perrone CM; Bae CJ; Pruitt AA; Lancaster E
J Neuroimmunol; 2019 Sep; 334():576980. PubMed ID: 31195181
[TBL] [Abstract][Full Text] [Related]
5. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance.
Martins F; Sofiya L; Sykiotis GP; Lamine F; Maillard M; Fraga M; Shabafrouz K; Ribi C; Cairoli A; Guex-Crosier Y; Kuntzer T; Michielin O; Peters S; Coukos G; Spertini F; Thompson JA; Obeid M
Nat Rev Clin Oncol; 2019 Sep; 16(9):563-580. PubMed ID: 31092901
[TBL] [Abstract][Full Text] [Related]
6. Paraneoplastic myelitis associated with durvalumab treatment for extensive-stage small cell lung cancer.
Wang L; Lou H; Li B; Li J; Yang YM
Invest New Drugs; 2022 Feb; 40(1):151-156. PubMed ID: 34287773
[TBL] [Abstract][Full Text] [Related]
7. Acute progressive neuropathy-myositis-myasthenia-like syndrome associated with immune-checkpoint inhibitor therapy in patients with metastatic melanoma.
Möhn N; Sühs KW; Gingele S; Angela Y; Stangel M; Gutzmer R; Satzger I; Skripuletz T
Melanoma Res; 2019 Aug; 29(4):435-440. PubMed ID: 30855529
[TBL] [Abstract][Full Text] [Related]
8. Inflammatory CNS disease caused by immune checkpoint inhibitors: status and perspectives.
Yshii LM; Hohlfeld R; Liblau RS
Nat Rev Neurol; 2017 Dec; 13(12):755-763. PubMed ID: 29104289
[TBL] [Abstract][Full Text] [Related]
9. Pathophysiology of paraneoplastic and autoimmune encephalitis: genes, infections, and checkpoint inhibitors.
Vogrig A; Muñiz-Castrillo S; Desestret V; Joubert B; Honnorat J
Ther Adv Neurol Disord; 2020; 13():1756286420932797. PubMed ID: 32636932
[TBL] [Abstract][Full Text] [Related]
10. Immune-related adverse events of checkpoint inhibitors: Insights into immunological dysregulation.
Yang H; Yao Z; Zhou X; Zhang W; Zhang X; Zhang F
Clin Immunol; 2020 Apr; 213():108377. PubMed ID: 32135278
[TBL] [Abstract][Full Text] [Related]
11. Neurologic Immune-Related Adverse Events Associated with Immune Checkpoint Inhibition.
Pan PC; Haggiagi A
Curr Oncol Rep; 2019 Nov; 21(12):108. PubMed ID: 31776691
[TBL] [Abstract][Full Text] [Related]
12. Advances in paraneoplastic neurological syndromes.
Honnorat J; Cartalat-Carel S
Curr Opin Oncol; 2004 Nov; 16(6):614-20. PubMed ID: 15627026
[TBL] [Abstract][Full Text] [Related]
13. Paraneoplastic Encephalitis and Enteric Neuropathy Associated With Anti-Hu Antibody in a Patient Following Immune-checkpoint Inhibitor Therapy.
Kang K; Zheng K; Zhang Y
J Immunother; 2020 Jun; 43(5):165-168. PubMed ID: 32195750
[TBL] [Abstract][Full Text] [Related]
14. Clinical characteristics of rheumatic syndromes associated with checkpoint inhibitors therapy.
Kostine M; Truchetet ME; Schaeverbeke T
Rheumatology (Oxford); 2019 Dec; 58(Suppl 7):vii68-vii74. PubMed ID: 31816082
[TBL] [Abstract][Full Text] [Related]
15. Autoimmune paraneoplastic syndromes associated to lung cancer: A systematic review of the literature: Part 3: Neurological paraneoplastic syndromes, involving the central nervous system.
Bentea G; Sculier C; Grigoriu B; Meert AP; Durieux V; Berghmans T; Sculier JP
Lung Cancer; 2017 Apr; 106():83-92. PubMed ID: 28285700
[TBL] [Abstract][Full Text] [Related]
16. Neurological toxicities associated with immune-checkpoint inhibitors.
Touat M; Talmasov D; Ricard D; Psimaras D
Curr Opin Neurol; 2017 Dec; 30(6):659-668. PubMed ID: 28938341
[TBL] [Abstract][Full Text] [Related]
17. Paraneoplastic neurological syndrome: growing spectrum and relevance.
Ganaraja VH; Rezk M; Dubey D
Neurol Sci; 2022 Jun; 43(6):3583-3594. PubMed ID: 35460452
[TBL] [Abstract][Full Text] [Related]
18. Hematological toxicities in immune checkpoint inhibitors: A pharmacovigilance study from 2014 to 2019.
Ye X; Hu F; Zhai Y; Qin Y; Xu J; Guo X; Zhuang Y; He J
Hematol Oncol; 2020 Oct; 38(4):565-575. PubMed ID: 32383782
[TBL] [Abstract][Full Text] [Related]
19. Management of immunotherapy toxicities in older adults.
Bhandari S; Gill AS; Perez CA; Jain D
Semin Oncol; 2018 Aug; 45(4):226-231. PubMed ID: 30446167
[TBL] [Abstract][Full Text] [Related]
20. Neurologic manifestations of autoimmunity with immune checkpoint inhibitors.
McCombe JA; Sechi E; Zekeridou A
Handb Clin Neurol; 2024; 200():449-465. PubMed ID: 38494296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
